| Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer LG KEYNOTE-189 Investigors, New England Journal of Medicine 378 (22), 2078-2092, 2018 | 6012 | 2018 |
| Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, .., SM Lee, ... New England journal of medicine 378 (2), 113-125, 2018 | 4719 | 2018 |
| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC FI SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, C ... New England Journal of Medicine 382 (1), 41-50, 2020 | 2299 | 2020 |
| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, .., SM Lee, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2279 | 2017 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial R Pirker, FLEX The Lancet 373 (9674), 1525-31, 2009 | 1834 | 2009 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1760 | 2017 |
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution EC De Bruin, N McGranahan, R Mitter, M Salm, DC Wedge, L Yates, ... Science 346 (6206), 251-256, 2014 | 1265 | 2014 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1232 | 2017 |
| Neoantigen-directed immune escape in lung cancer evolution T consortium Nature 567 (7749), 479-485, 2019 | 778 | 2019 |
| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 653 | 2020 |
| Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis CK Lee, C Brown, RJ Gralla, V Hirsh, S Thongprasert, CM Tsai, EH Tan, ... Journal of the National Cancer Institute 105 (9), 595-605, 2013 | 617 | 2013 |
| Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data A Rossi, M Di Maio, P Chiodini, RM Rudd, H Okamoto, .., SM Lee Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2012 | 587 | 2012 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 566 | 2018 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 431 | 2017 |
| Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. NM Bleehen, ES Newlands, SM Lee, N Thatcher, P Selby, AH Calvert, ... Journal of Clinical Oncology 13 (4), 910-913, 1995 | 367 | 1995 |
| Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial MF Muers, RJ Stephens, P Fisher, L Darlison, CM Higgs, E Lowry, ... Lancet 371 (9625), 1685-94, 2008 | 351 | 2008 |
| Tracking genomic cancer evolution for precision medicine: the lung TRACERx study M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive, S Quezada, ... PLoS biology 12 (7), e1001906, 2014 | 315 | 2014 |
| Lung adenocarcinoma promotion by air pollutants W Hill, EL Lim, CE Weeden, C Lee, M Augustine, K Chen, FC Kuan, ... Nature 616 (7955), 159-167, 2023 | 308 | 2023 |
| Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma M Brada, S Stenning, R Gabe, LC Thompson, D Levy, .., SM Lee J Clin Oncol 28 (30), 4601-4608, 2010 | 292 | 2010 |
| Geospatial immune variability illuminates differential evolution of lung adenocarcinoma LQJ AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca ... Nat Med 26 (7), 1054-1062, 2020 | 246 | 2020 |
